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Gut dysbiosis is associated with development of metabolic syndrome in Tlr5/ mice, but the underlying
mechanism remains unclear. In this issue, Singh et al. (2015) report that augmented SCFA levels play a dele-
terious role in metabolic syndrome by promoting conversion of SFA to oleate in Tlr5/ mice via increased
liver SCD1expression.Metabolic syndrome encompasses
numerous clinical manifestations
including obesity, type 2 diabetes (T2D),
and cardiovascular diseases and results
from a complex interaction between host
genetics and environmental factors. The
intestinal microbiota has taken the center
stage among environmental factors impli-
cated in the development of metabolic
syndrome, as it nicely integrates nutri-
tional, genetic, and immune factors. The
intestine is a complex milieu where a
multitude of microorganisms including
bacteria, fungi, and viruses interact daily
with luminal contents and host cells to
impact numerous physiological pro-
cesses such as immunity, development,
and metabolism. Although functional
interaction between the microbiota and
surrounding mucosal cells (epithelial and
immune cells) were reported, further
investigation uncovered a number of
microbe-mediated extra-intestinal bio-
logical effects that greatly impact host en-
ergy metabolism and cardiometabolic
regulation (Ba¨ckhed et al., 2012). It is
now well-established that microbial
composition is altered in obese subjects
compared to healthy lean controls and
that metabolic syndrome is observed
following transfer of this biota into germ-
free mice. Moreover, altering innate im-
mune response through genetic ablation
of the Tlr5 gene (T5KO) promotes a state
of sub-chronic inflammation and microbi-
al dysbiosis leading to the development of
metabolic syndrome, a phenotype that is
also transmissible by microbial transplan-
tation (Vijay-Kumar et al., 2010). Dysregu-
lated microbiota balance and metabolic954 Cell Metabolism 22, December 1, 2015 ªsyndrome originated from intestinal
epithelial cell-derived TLR5 signaling
(Chassaing et al., 2014). Although these
observations highlighted the key role of
microbes and innate signaling in meta-
bolic syndrome, the mechanism underly-
ing this pathological response remains
unclear.
A recent publication by Singh et al.
(2015) sheds new light into the interaction
between host genetic, diet, and microbi-
al-derivedmetabolites. The authors found
that the absence of TLR5 signaling pro-
motes microbial dysbiosis and hepatic
dyslipidemia, particularly the conversion
of lipotoxic saturated fatty acids to
C18:1 (oleate). These metabolic changes
correlated with metabolic syndrome
development, increased production of
SCFAs, enhanced expression of intestinal
SCFA receptors, and augmented hepatic
stearoyl CoA desaturase-1 (SCD1) gene
expression in T5KO mice. Importantly,
elevated hepatic lipogenesis and meta-
bolic syndrome were not observed in
germ-free T5KO mice or mice exposed
to antibiotic regimen, highlighting the key
role of the microbiota in liver steatosis
and metabolic syndrome. Mechanisti-
cally, administration of dietary SCFAs re-
sulted in increased hepatic oleate levels,
in association with metabolic syndrome
features in T5KO mice, while WT counter-
parts show no adverse phenotype. Liver-
specific deletion of SCD1 resulted in
reduced adiposity, lower hepatic oleate
levels, and improved insulin sensitivity in
T5KO mouse compared to control mice,
but did not reduce SCFAs production.
Therefore, the relationship between gut2015 Elsevier Inc.bacteria and these host events involves
two interrelated phenomena with mi-
crobes generating SCFAs, which contrib-
utes to induce the expression of hepatic
SCD1, both steps being critical for devel-
opment of liver steatosis and metabolic
syndrome. The mechanism by which
microbes induce SCD1 expression is
unknown but is likely independent of Tlr2
or Tlr4, since their genetic deletion
failed to rescue metabolic syndrome in
T5KO mice (Vijay-Kumar et al., 2010).
Altogether, these findings reveal how
defective TLR5 signaling augments mi-
crobial-derived SCFA production, which
then induces SCD1-dependent lipogen-
esis and insulin resistance (Figure 1).
The observation that dietary SCFAs,
including butyrate, enhance metabolic
syndrome in T5KO is quite provocative
and challenges pre-existing notions about
the anti-inflammatory and therapeutic ef-
fect of these microbial metabolites on
obesity-linked T2D. On the latter point,
microbiome analysis of obese subjects
or patients with T2D showed a depletion
of butyrate-producing bacteria (Tilg and
Moschen, 2014), though without quanti-
fying the actual metabolite in the liver.
Importantly, SCFAs, including butyrate
and proprionate, have been shown to
improve insulin sensitivity and glucose
homeostasis in animal models of meta-
bolic syndrome (Canfora et al., 2015). In
addition, genetic studies indicated that
the SCFA receptor Gpr43 is critical for
prevention of HFD-induced insulin resis-
tance in mice (Kimura et al., 2013). There-
fore, the discordant relationship between
the protective and deleterious effect of
Figure 1. Gut Microbiota-Derived SCFAs Drives Hepatic Lipogenesis and Metabolic
Syndrome in T5KO Mice
Toll-like receptor 5-deficient (T5KO) mice displayed sub-chronic inflammation, which promotes intestinal
microbial dysbiosis with concomitant increased SCFA-receptor expression and portal SCFA levels. Mi-
crobial-derived SCFAs contribute to insulin resistance and development of metabolic syndrome through
augmented stearoyl CoA desaturase-1 (SCD1)-dependent conversion of lipotoxic saturated fatty acids
(C16:0-C18:0) to steatotic C18:1 (oleate).
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related to their production level (high in
T5KO) and/or site of action (local versus
periphery). Both a sub-chronic inflamma-
tory environment and elevated expression
of SCD1 are critical requirements for
SCFAs to exacerbate metabolic syn-
drome, since administration of SCFA
failed to impair metabolic outcomes in
WT mice. It would be important to define
the relationship between SCFA level and
host response in different models of
metabolic syndrome in which gut immu-
nity is not as severely compromised.Another important observation from the
study of Singh et al. is that although
SCFAs have been shown to inhibit inflam-
mation (Tan et al., 2014), the levels of
several inflammatory genes and markers
were unaltered by dietary supplementa-
tion of SCFAs in T5KO mice, whereas
metabolic syndrome was exacerbated.
This suggests that in the T5KO model,
dietary SCFAs operate through an in-
flammation-independent pathway, likely
enhancing expression of SCD1, the crit-
ical event for metabolic syndrome devel-
opment. Whether SCFA increased SCD1Cell Metabolism 22,expression through a histone deacety-
lase- or GPR41/43 receptor-dependent
mechanism in the liver will require further
investigation.
While the Singh et al. study focuses on
hepatic lipogenesis, the potential impact
of microbiota and dietary-derived SCFAs
on liver gluconeogenesis and muscle
glucose disposal remains to be clarified
in this model. Indeed, proprionate is a
key gluconeogenic precursor, and previ-
ous studies in animal models have shown
that SCFAs increase lipid oxidation and
improve insulin action in skeletal muscle
(Canfora et al., 2015). Moreover, the au-
thors found that T5KO mice have a
marked reduction in the expression of
the GLUT4 glucose transporter in muscle,
which was partially rescued by liver-tar-
geted SCD1 deletion, suggesting that
TLR5 signaling controlsmuscle insulin ac-
tion through a mechanism involving
SCFAs and a yet unknown hepatic factor
under SCD1 regulation. More studies will
be needed to ascertain tissue-specific in-
sulin action on glucose turnover using
tracer-coupled hyperinsulinemic-eugly-
cemic clamp experiments and to define
the events leading to increased SCFA
levels and SCFA receptors in T5KO
mice. Since microbiota studies have not
previously reported difference in abun-
dance of SCFA-producing microbes be-
tween T5KO and WT mice (Leifer et al.,
2014; Vijay-Kumar et al., 2010), the
source of microbial-derived SCFAs re-
mains elusive.
In conclusion, these findings provide
novel and intriguing insights into the inter-
play between microbial-derived SCFAs
and host energy homeostasis. The study
highlights the need to carefully evaluate
the role ofmicrobial metabolites in various
models of metabolic syndrome and in
obese T2D subjects. Interestingly, while
SCFA are generally thought to reduce
colorectal cancer, it was recently reported
that butyrate promote carcinogenic
development in ApcMin/+;Msh2/ mice
(Belcheva et al., 2014), further suggesting
that increased production of these me-
tabolites may not always correlate with
beneficial outcomes.ACKNOWLEDGMENTS
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The role of reactive oxygen species (ROS) and antioxidants in cancer is controversial because of their
context-dependent ability to promote or suppress tumorigenesis. Piskounova et al. (2015) now show that
ROS limit distant metastasis: only cells with increased antioxidant capacity are able to succeed in their pur-
pose to metastasize.Tumor metastasis is the main cause of
death in cancer patients. The acquisition
of specific traits by cancer cells,
including migration, invasion, and sur-
vival in the bloodstream, permits metas-
tasis. Of all the tumor cells that reach
the circulation, only a few are able to
generate metastases in distant organs.
Emerging evidence suggests that oxida-
tive stress acts as a key driver of the
malignant transformation observed in pri-
mary tumors that enhances their meta-
static potential. In a recent Nature paper,
Piskounova et al. show that increased
production of reactive oxygen species
(ROS) is essential to enable and sustain
a highly metastatic phenotype (Piskou-
nova et al., 2015).
ROS, including hydrogen peroxide
(H2O2) and superoxide (O2
d) and hy-
droxyl (HOd) free radicals, are mainlyproduced during oxygen-consuming
metabolic reactions that occur in peroxi-
somes, the endoplasmic reticulum, and
the mitochondria, which is their major
source. Moderate ROS levels have
been shown to support cell proliferation
and migration and activate stress-
induced signaling pathways involved in
cell survival, therefore contributing to tu-
mor development (Gorrini et al., 2013).
Accordingly, the use of antioxidants to
quench oxidative stress has been postu-
lated as a preventive and therapeutic
anticancer strategy. Thus, large-scale
clinical trials using antioxidant supple-
mentation have been conducted, though
they failed to benefit patients and even
increased cancer incidence (Sayin
et al., 2014). Considering the relevance
of oxidative stress in cancer develop-
ment, why have many clinical trialsbased on antioxidant supplementation
not shown therapeutic efficacy? One
possibility is that excessive ROS accu-
mulation promotes severe cellular dam-
age and triggers apoptosis, which makes
a tight redox regulation essential for the
cell. Indeed, cancer cells depend on an
increased antioxidant capacity, which
keeps ROS levels higher than in normal
cells, but below a critical threshold able
to maintain their viability. It has been
observed that the same stimuli that pro-
mote oxidative stress, such as detach-
ment from the cell matrix, also increase
the selective pressure on cells to adapt
by building up a powerful antioxidant
response (Gorrini et al., 2013).
The study performed by Piskounova
et al. supports that notion. To identify
the mechanistic differences in the meta-
static activity of several melanomas, the
